Skip to content

Stocks To Cash In On The $35 Billion NASH Dash

Non-alcoholic steatohepatitis (NASH) is expected to become the leading cause of all liver transplants by 2020 – and there is currently no approved treatment for it. As such, this once obscure disease has become a top area of focus for drug makers, and as today’s article notes, “NASH is also predicted to be the next huge market opportunity for the biopharmaceutical industry, with some forecasting a global market size of as much as $35 billion per year.” For investors looking to cash in on the NASH dash, the author highlights a number of biopharmaceutical stocks to consider. For more, CLICK HERE.